Merus N.V. (MRUS)

48,36 +0,86 (+1,81 %) À la clôture : 04:00PM EDT

Merus N.V.

Uppsalalaan 17
3rd & 4th floor
Utrecht 3584 CT
Netherlands
31 30 253 8800
https://www.merus.nl

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 172

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Sven Ante Lundberg M.D.	CEO, President & Executive Director	1,11M	S.O.	1963
Mr. Gregory D. Perry	Chief Financial Officer	419,1k	S.O.	1960
Mr. Peter B. Silverman J.D.	EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal	781,84k	565,02k	1978
Dr. Hui Liu Ph.D.	Chief Business Officer, Executive VP & Head of Merus U.S.	640,14k	1,8M	1967
Dr. Andrew Joe M.D.	Chief Medical Officer & Senior VP	685,12k	S.O.	1967
Dr. Hennie Hoogenboom	Co-Founder and Scientific Advisor	S.O.	S.O.	S.O.
Harry Shuman	Chief Accounting Officer	S.O.	S.O.	S.O.
Mr. Cornelis Adriaan de Kruif Ph.D.	CTO & Executive VP	347,54k	S.O.	1965
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.	Chief Scientific Officer & Senior VP	S.O.	S.O.	S.O.
Kathleen Farren	IR & Corporate Communications Officer	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Merus N.V. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.